Results 201 to 210 of about 27,196 (258)

Incidence and Survival of Hemophagocytic Lymphohistiocytosis Over Two Decades: A Population‐Based Study

European Journal of Haematology, Volume 117, Issue 1, Page 210-218, July 2026.
ABSTRACT Adult hemophagocytic lymphohistiocytosis (HLH) is a rare, life‐threatening syndrome triggered by various conditions. A nationwide study of the incidence and outcomes of HLH in Denmark over 23 years (2000–2023) was performed. Adults (≥ 18 years) with HLH and triggering diseases were identified in the Danish National Patient Registry and/or the ...
Mads Okkels Birk Lorenzen, Martin Jensen, Rasmus Rask Kragh Jørgensen, Paw Jensen, Henrik Frederiksen, Dennis L. Hansen, Daniel El Fassi, Morten Nørgaard Andersen, Tarec Christoffer El‐Galaly   +8 more
wiley   +1 more source

EGFR- and HER3-targeted bispecific antibody-drug conjugate demonstrates antitumor activity in metastatic castration-resistant prostate cancer. [PDF]

J Clin Invest
Fang B, Li X, Lu Y, Ma W, Gan H, Zhang T, Liu Q, Wang B, Wang Z, Zhu Y, Zhu H, Xiao S, Bian X, Wei G, Ye D, Zhu Y.   +15 more
europepmc   +1 more source

Loncastuximab Tesirine in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: Evidence and Practical Guidance From Italian Clinical Experience

European Journal of Haematology, Volume 117, Issue 1, Page 144-153, July 2026.
ABSTRACT Patients with relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) who progress to the third‐line setting face a lack of standardized treatment, despite the presence of multiple available therapies. In this context, antibody–drug conjugates represent a relatively new class of anticancer agents; among them, loncastuximab tesirine is ...
Francesca Bonello, Andrea Aroldi, Alessia Castellino, Lara Mannelli, Elia Boccellato, Serena Rosati, Luisa Verga, Umberto Vitolo   +7 more
wiley   +1 more source

Linvoseltamab in multiple myeloma: a BCMA × CD3 bispecific antibody for relapsed and refractory disease. [PDF]

Ann Med Surg (Lond)
Khan G, Haider E, Imtiaz A, Ekouo J.
europepmc   +1 more source

Transitioning CAR‐T therapy for multiple myeloma to the outpatient setting: First clinical insights with cilta‐cel in Germany

HemaSphere, Volume 10, Issue 7, July 2026.
Christof Scheid, Philipp Gödel, Christopher Krone, Elisa Carpinteiro, Michael Hallek, Udo Holtick, Tim Richardson   +6 more
wiley   +1 more source

Navigating the Future of Respiratory Infections: Key Insights From International Congress in Singapore, 17–20 September 2025

Influenza and Other Respiratory Viruses, Volume 20, Issue 7, July 2026.
ABSTRACT Background The 8th International Society for Respiratory Viruses (ISRV) Antiviral Group Conference, held jointly with the 3rd International Meeting on Respiratory Pathogens in Singapore (17–20 September 2025), examined evolving approaches to prevention and management of respiratory infections.
Narmadha Morvil, Wilson Guo Wei Goh, Charlotte Zheng, Stephanie Sutjipto, Dorothy Hui Lin Ng, Maria Zambon   +5 more
wiley   +1 more source

CM512, a potentially novel IgG1-based bispecific antibody dual-targeting TSLP and IL-13, for the suppression of type 2 inflammation. [PDF]

J Transl Med
Yang Y, Lan Y, Bian L, Li Y, Song Q, Gao X, Hou Q, Bai Y, Chen B.   +8 more
europepmc   +1 more source

Extracorporeal Cytokine Hemadsorption for the Treatment of Severe Steroid Refractory Cytokine Release Syndrome Secondary to T‐Cell Immunotherapy for B‐Cell Malignancies: A Case Series

Hematological Oncology, Volume 44, Issue 4, July 2026.
Gianluca Cavallaro, Silvia Ferrari, Anna Pollastri, Elena Di Credico, Cristian Meli, Monica Rondi, Alessandro Putelli, Federico Lussana, Anna Grassi, Alessandro Rambaldi, Tino Martino Valetti, Ivano Riva, Giuseppe Gritti   +12 more
wiley   +1 more source

First-in-human, phase 1 study of CM512, a TSLP/IL-13 bispecific antibody, in healthy volunteers: safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity. [PDF]

Front Immunol
Cheng Y, Liu Q, Li M, Xie Y, Men Y, He M, Wang H, Feng X, Zeng M, Zhang L, Chen B, Li J, Feng P.   +12 more
europepmc   +1 more source

A bispecific antibody designed to act as a NRP2/PLXNA1 agonist mimics anticancer activity of SEMA3F. [PDF]

J Biol Chem
Tian H, Fung CP, Burman L, Chong YE, Liu C, Geng Y, Yang L, Chow MW, Zhang Y, Ho KWH, Zhu G, Wu Z, Yang XL, Xu Z, Nangle LA.   +14 more
europepmc   +1 more source